Financial Performance Evaluation of Pharmaceutical Companies in Southeast Asia: The Influence of Cash Conversion Cycle, Sales Growth and Firm Size During the COVID-19 Pandemic
Abstract
This study investigates the effects of the Cash Conversion Cycle (CCC), sales growth, and firm size on the financial performance of pharmaceutical companies in Southeast Asia during the COVID-19 pandemic (2020–2021). The research focuses on pharmaceutical firms listed in Indonesia, Singapore, and Malaysia, with a total sample of [insert number] companies. Using secondary data collected from Bloomberg, the study employs a quantitative approach and applies multiple linear regression analysis, with Return on Assets (ROA) serving as the indicator of financial performance. The results reveal that CCC has no significant impact on ROA, while sales growth negatively affects ROA, and firm size positively influences ROA. These findings suggest that during periods of global disruption like the pandemic, firm size becomes a key driver of financial resilience, while aggressive sales growth strategies may undermine profitability, possibly due to increased operational risks and supply chain challenges. Although CCC efficiency did not significantly impact profitability in this context, managing firm scale and adapting growth strategies remain crucial for sustaining financial performance during crises.
Keywords: Cash Conversion Cycle, Sales Growth, Firm Size, Return on Assets.
Downloads
Downloads
Published
Issue
Section
License
Authors who publish with this journal agree to the following terms:
The journal allow the authors to hold the copyright without restrictions and allow the authors to retain publishing rights without restrictions.
The journal allow the authors to hold the copyright without restrictions and allow the authors to retain publishing rights without restrictions. Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).
This work is licensed under a Creative Commons Attribution 4.0 International License.
